Navigation Links
Nobel Winner Baruch Blumberg, Viral Genetics Advisor, Dies at 85
Date:4/8/2011

SAN MARINO, Calif., April 8, 2011 /PRNewswire/ -- Dr. Baruch S. Blumberg, a Nobel Prize winning scientist and advisor to Viral Genetics, Inc. (Pinksheets: VRAL), died April 5 at the age of 85. Dr. Blumberg died after apparently suffering a heart attack while attending a conference at NASA's Ames Research Center at Moffett Field near San Jose, California.

"We are very sad to hear of Dr. Blumberg's passing, and our condolences go out to his friends and family," said Viral Genetics' CEO, Haig Keledjian. "His insights and life-saving work have truly been an inspiration to me personally and those with whom he worked. His humble nature also just made it a pleasure to be around Dr. Blumberg and to work with him. He will be sorely missed."

Dr. Baruch S Blumberg, MD, Ph.D., joined the Viral Genetics advisory board in 2010. As the leading expert on the HBV virus, Dr. Blumberg assisted Viral Genetics and lead Research Dr. M. Karen Newell Rogers in understanding the genetics of chronic HBV infection in the pursuit of a Targeted Peptide-based compound to treat it. "I am deeply saddened by the loss of Dr. Blumberg," said Newell Rogers. "He was an amazing human being who can be credited with saving millions of lives as a result of his discoveries and his dedication to humanity."

Dr. Blumberg discovered the Hepatitis-B virus and developed a diagnostic test for its detection, and was a co-recipient of the 1976 Nobel Prize in Physiology or Medicine. He and a colleague, Irving Millman, also created the first retroviral vaccine for protection from Hepatitis-B. Over 1 billion doses of the vaccine have been administered since 1982, with chronic infection rates among children plummeting in many countries. As a result, Dr. Blumberg has been credited with saving millions of lives.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A majority-owned subsidiary called VG Energy (www.vgenergy.net) is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at www.viralgenetics.com

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

www.viralgenetics.com

Contact:

Haig Keledjian
Viral Genetics, Inc.
626-334-5310
info@viralgenetics.com


'/>"/>
SOURCE Viral Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Graphene pioneers follow in Nobel footsteps
2. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
3. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
4. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
5. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
6. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
7. Thomson Reuters Predicts Nobel Laureates
8. Nobelprize.org Expands Channels and News Services for the 2009 Nobel Prize Announcements
9. Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel
10. BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge
11. Protege of Nobel Prize Winner Robert Edwards Carries on his IVF Legacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... ... NDA Partners Chairman Carl Peck, MD , announced today that John W. ... Center for Devices and Radiological Health and recognized leader in the medical device, pharmaceutical ... his FDA experience, Dr. Sheets served in senior technical leadership roles in a series ...
(Date:8/21/2017)... USA (PRWEB) , ... August 20, 2017 , ... ... the Journal of Biomedical Optics (JBO) starting 1 January 2018. The journal is ... of Biomedical Optics publishes papers on the use of modern optical technology for ...
(Date:8/21/2017)... ... August 21, 2017 , ... The team at ... educational webinar, in which attendees will learn about the assembly and topological architecture ... with an overview of the development and validation of new high-quality recombinant monoclonal ...
(Date:8/17/2017)... Westlake Village, CA (PRWEB) , ... August 17, ... ... biopsy technology for cancer research and personalized medicine, today announced the launch of ... in Kansas City, Missouri. The study’s goal is to evaluate the potential for ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):